Propensity-matched analysis of stage-specific efficacy of adjuvant chemotherapy for bladder cancer

Chen, Felix V.; Koru‐Sengul, Tulay; Mao, Feng; Jue, Joshua S.; Alameddine, Mahmoud; Dave, Devina J.; Punnen, Sanoj; Parekh, Dipen J.; Ritch, Chad R.; Gonzalgo, Mark L.

doi:10.1016/j.urolonc.2019.06.022

Cited by 3 publications

(5 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chen et al studied the impact of AC on OS in 3066 patients who underwent RC for any pT, N0-1, or M0 bladder cancer. 9 In patients with pT2N0, AC did not reveal a significant difference in OS compared with RC alone and may not significantly impact the prognosis of the patients with localized disease. Thus, patients with cT2 and ypT2 tumours, who are likely to have organ-confined disease, may not necessarily benefit from AC and do not necessarily require adjuvant nivolumab.…”

Section: Hermans Et Al Examined the Effect Of Neoadjuvant Treatment O...mentioning

confidence: 76%

“…Several studies have revealed no significant differences in overall survival (OS) between the cT2 group with NAC followed by RC and RC alone. 2,9,10 The 5-year OS was also higher in both groups than in the cT ≥ 3. Furthermore, a recent study revealed that NAC did not have a significant survival effect on patients with cT2N0 who were downstaged to pT < 2.…”

Section: Introductionmentioning

confidence: 85%

“…Therefore, we need to analyse the impact of AC in pT2, an organ‐confined disease, and pT3/4, a non‐organ‐confined disease. Chen et al studied the impact of AC on OS in 3066 patients who underwent RC for any pT, N0‐1, or M0 bladder cancer 9 . In patients with pT2N0, AC did not reveal a significant difference in OS compared with RC alone and may not significantly impact the prognosis of the patients with localized disease.…”

Section: Discussionmentioning

confidence: 99%

“…Several studies have revealed no significant differences in overall survival (OS) between the cT2 group with NAC followed by RC and RC alone 2,9,10 . The 5‐year OS was also higher in both groups than in the cT ≥ 3.…”

Section: Introductionmentioning

confidence: 99%

“…The 5‐year OS was also higher in both groups than in the cT ≥ 3. Furthermore, a recent study revealed that NAC did not have a significant survival effect on patients with cT2N0 who were downstaged to pT < 2 9 . It is unclear whether adjuvant chemotherapy (AC) improves the prognosis of patients with cT2 who receive NAC and are likely to have a low risk of recurrence.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

New risk stratification for adjuvant nivolumab for high‐risk muscle‐invasive urothelial carcinoma

Saito,

Kanao,

Matsumoto

et al. 2023

BJUI Compass

View full text Add to dashboard Cite

ObjectivesWe aim to evaluate the risk of recurrence after neoadjuvant chemotherapy followed by radical cystectomy, particularly in ypT2 disease in patients with urothelial carcinoma, because it is not clear if all eligible patients with high‐risk muscle‐invasive urothelial carcinoma should be treated with adjuvant nivolumab.Materials and MethodsWe analysed the radiological and clinicopathological features, including cT and ypT stages, of 197 patients who had undergone two to four cycles of cisplatin‐based neoadjuvant chemotherapy and radical cystectomy without adjuvant chemotherapy. We stratified the risk of postoperative recurrence by these factors.ResultsThe median observation period was 29.6 (interquartile range, 11.4–71.7) months, and disease recurrence was observed in 58 patients. Multivariate analysis revealed that ypT stage (P = 0.019) and lymphovascular invasion (P = 0.015) were independent risk factors for postoperative recurrence. The ypT2 group (n = 38) had significantly better recurrence‐free survival than the ypT3 group (n = 41) (median recurrence‐free survival: not reached vs. 13.4 months, respectively, P = 0.005). In ypT2 disease, the cT2 and ypT2 group (n = 15), which was diagnosed as cT2 preoperatively and then diagnosed as ypT2 postoperatively, had significantly better recurrence‐free survival than the cT3/4 and ypT2 group (n = 23) (median recurrence‐free survival: not reached vs. 63.1 months, respectively, P = 0.034). There was no significant difference in recurrence‐free survival between the ypT ≤ 1 (n = 106) and the cT2 and ypT2 groups (median recurrence‐free survival: not reached in both, P = 0.962).ConclusionPatients with cT2 and ypT2 stage have a relatively low risk of recurrence and thus have a lower need for adjuvant nivolumab, particularly those with ypT2.

show abstract

Section: Hermans Et Al Examined the Effect Of Neoadjuvant Treatment O...mentioning

confidence: 76%

Section: Introductionmentioning

confidence: 85%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

New risk stratification for adjuvant nivolumab for high‐risk muscle‐invasive urothelial carcinoma

Saito,

Kanao,

Matsumoto

et al. 2023

BJUI Compass

View full text Add to dashboard Cite

show abstract

Adjuvant chemotherapy versus observation following radical cystectomy for locally advanced urothelial carcinoma of the bladder

Bharadwaj

Kaul

Fleishman

et al. 2022

Urologic Oncology: Seminars and Original Investigations

View full text Add to dashboard Cite

Salvage radical cystectomy after organ preservation therapy in patients with undifferentiated bladder cancer: its place in the treatment algorithm and survival results

Yakovlev

Kliushyn

2020

ZMJ

View full text Add to dashboard Cite

Недифференцированный рак мочевого пузыря (G4 РМП) -агрессивное заболевание с высоким потенциалом к метастазированию и рецидивированию. На момент диагностики такие больные имеют мышечно-инвазивную форму, что требует радикальной цистэктомии (РЦЭ).

show abstract

Propensity-matched analysis of stage-specific efficacy of adjuvant chemotherapy for bladder cancer

Cited by 3 publications

References 26 publications

New risk stratification for adjuvant nivolumab for high‐risk muscle‐invasive urothelial carcinoma

New risk stratification for adjuvant nivolumab for high‐risk muscle‐invasive urothelial carcinoma

Adjuvant chemotherapy versus observation following radical cystectomy for locally advanced urothelial carcinoma of the bladder

Salvage radical cystectomy after organ preservation therapy in patients with undifferentiated bladder cancer: its place in the treatment algorithm and survival results

Contact Info

Product

Resources

About